Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

• Status: Recruiting
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Favipiravir

Criteria

Inclusion Criteria:

1. Clinically diagnosed with Corona Virus Disease 2019

2. Increased interleukin-6

3. Sign the informed consent

4. Subjects who can take medicine orally

5. Agree to collect clinical samples

6. Female subjects of childbearing age are not pregnant and agree to take effective contraception within 7 days of the last oral medication to ensure that they are not pregnant within 3-6 months

7. Male patients agree to effective contraception within 7 days of last oral medication.

Exclusion Criteria:

1. Cases of severe vomiting that make it difficult to take the drug orally

2. Allergic to Favipiravir or tocilizumab

3. Pregnant and lactating women

4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within one week before admission.

5. Cases of respiratory failure and requiring mechanical ventilation

6. Cases of shock

7. Combined organ failure requires ICU monitoring and treatment

8. Predicted clinically that there is no hope of survival, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission

9. Alanine aminotransferase / Aspartate aminotransferase> 5 times of upper limit of normal

10. Neutrophils <0.5 × 10^9 / L, platelets less than 50 × 10^9 / L

11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases

12. Long-term oral anti-rejection drugs or immunomodulatory drugs

13. Allergic reactions to tocilizumab or any excipients

14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal infections

15. Organ transplant patients

16. Patients with mental disorders